SCHEMBL30293256

SCHEMBL30293256

COc1ccc(NS(C)(=O)=O)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR4 Q5NUL3 3/20 0.56
GAA P10253 2/20 0.51
PTGS1 P23219 3/20 0.50
PTGS2 P35354 2/20 0.50
CA12 O43570 2/20 0.48
CA1 P00915 2/20 0.48
CA2 P00918 2/20 0.48
CA9 Q16790 2/20 0.48
KEAP1 Q14145 1/20 0.47
TNIK Q9UKE5 1/20 0.47
PTK2 Q05397 1/20 0.47
LMNA P02545 1/20 0.46
MAPK1 P28482 1/20 0.46
SLC22A12 Q96S37 1/20 0.46
RAB9A P51151 1/20 0.46
ADRA2A P08913 1/20 0.45
ADRA2C P18825 1/20 0.45
ADRA1D P25100 1/20 0.45
ADRA1A P35348 1/20 0.45
ADRA1B P35368 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2760304 1.00 FFAR4 (0.56) FFAR4GAAPTGS1PTGS2CA12
SCHEMBL27182657 0.83 FFAR4 (0.57) FFAR4GAACA12CA1CA2
SCHEMBL18088625 0.81 ALDH1A1 (0.50) FFAR4GAACA12CA1CA2
SCHEMBL26906975 0.81 PTGS1 (0.48) FFAR4GAAPTGS1PTGS2CA1
SCHEMBL18088805 0.80 KIF11 (0.55) FFAR4KEAP1
SCHEMBL17917629 0.80 PTGS1 (0.54) FFAR4GAAPTGS1PTGS2CA12
SCHEMBL11671246 0.80 FFAR4 (0.51) FFAR4GAACA12CA1CA2
SCHEMBL12678553 0.79 FFAR4 (0.40) FFAR4KEAP1RAB9AADRA2AADRA2C
SCHEMBL2737218 0.78 L3MBTL1 (0.56) GAAPTGS1PTGS2CA1CA2
SCHEMBL30505740 0.78 ERN1 (0.51) GAAPTGS1PTGS2PTK2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025072673-A1 THIAZOLE DERIVATIVES AND THEIR USE AS IRE 1 INHIBITORS AL22.02.01, INC. (US) 2025-04-03 WO disclosed
WO-2024249254-A2 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 WO disclosed
EP-4465982-A2 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2024-11-27 EP disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 WO disclosed
CN-109988093-B Amine compound for inhibiting SSAO/VAP-1 and application thereof in medicine 广东东阳光药业有限公司 2023-04-07 CN disclosed